Daniel Vigo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Daniel Vigo has a total of 274 co-authors. Here are the top co-authors by number of shared publications:
- Angel Y. Wang
University of British Columbia
11 shared publications - Kristen L. Hudec
Department of Psychiatry, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada
9 shared publications - Ronald C. Kessler
Department of Health Care Policy Harvard Medical School Boston Massachusetts USA
9 shared publications Lonna Munro
Department of Psychiatry, Faculty of Medicine, University of British Columbia, Vancouver, Canada
7 shared publications- Richard J. Munthali
Department of Psychiatry, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada
7 shared publications - Calista Leung
Department of Psychiatry, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada
6 shared publications
Latest Publications
- 5 November 2026
- Published by Springer Nature
- p. 1-22
COVID-19 and Excess Mortality in People with Mental Disorders: Lessons for Pandemic Preparedness
- 5 November 2026
- Published by Springer Nature
- p. 1-22
COVID-19 and Excess Mortality in People with Mental Disorders: Lessons for Pandemic Preparedness
- Open Access
- 29 October 2026
- Published by Elsevier in SSM - Mental Health
- Vol. 10
A social-ecological analysis of psychological self-management among college students
- 29 October 2026
- Published by Elsevier in SSM - Mental Health
- Vol. 10
Open AccessA social-ecological analysis of psychological self-management among college students
- 27 October 2026
- Published by SAGE Publications in The Canadian Journal of Psychiatry
From Target to Trial: Artificial Intelligence in Psychiatric Drug Development
Plain Language Summary: How Artificial Intelligence Could Improve Psychiatric Drug Development Developing new medicines for mental health conditions is difficult, expensive, and often unsuccessful. One reason is that people with the same diagnosis can differ greatly in their underlying biology and in how they respond to treatment. Clinical trials also rely heavily on symptom ratings and can be affected by placebo responses. This editorial explains how artificial intelligence (AI) could help at several stages of psychiatric drug development. AI can help researchers identify promising drug targets, design new treatment molecules, and use biological, brain-imaging, and clinical data to predict treatment response and improve clinical trials. Emerging approaches include digital twins, synthetic control groups, and digital measures of symptoms and behaviour. However, these technologies are still developing and should not be viewed as a solution to all the challenges of psychiatric drug development. Wider use will require representative datasets, strong data governance, transparent and interpretable models, rigorous clinical validation, and appropriate regulation.
- 27 October 2026
- Published by SAGE Publications in The Canadian Journal of Psychiatry
From Target to Trial: Artificial Intelligence in Psychiatric Drug Development
Plain Language Summary: How Artificial Intelligence Could Improve Psychiatric Drug Development Developing new medicines for mental health conditions is difficult, expensive, and often unsuccessful. One reason is that people with the same diagnosis can differ greatly in their underlying biology and in how they respond to treatment. Clinical trials also rely heavily on symptom ratings and can be affected by placebo responses. This editorial explains how artificial intelligence (AI) could help at several stages of psychiatric drug development. AI can help researchers identify promising drug targets, design new treatment molecules, and use biological, brain-imaging, and clinical data to predict treatment response and improve clinical trials. Emerging approaches include digital twins, synthetic control groups, and digital measures of symptoms and behaviour. However, these technologies are still developing and should not be viewed as a solution to all the challenges of psychiatric drug development. Wider use will require representative datasets, strong data governance, transparent and interpretable models, rigorous clinical validation, and appropriate regulation.
- Open Access
- 11 June 2026
- Published by Royal College of Psychiatrists in BJPsych Open
- Vol. 12 (4) , e160
Artificial intelligence (AI) psychosis: mechanisms, clinical risks and safety considerations in generative AI chatbots
Summary: As generative artificial intelligence chatbots become embedded in everyday life, concerns about their psychological risks are growing. Emerging reports describe cases of artificial intelligence-induced or -associated psychosis (hereafter artificial intelligence (AI) psychosis) in which intensive chatbot use is associated with delusional thinking patterns. This paper proposes a provisional mechanism wherein baseline user vulnerabilities and engagement patterns interact with generative artificial intelligence characteristics, such as sycophancy and hallucination, contributing to delusional ideation. It subsequently outlines clinical, design and regulatory strategies that may help mitigate risks.
- 11 June 2026
- Published by Royal College of Psychiatrists in BJPsych Open
- Vol. 12 (4) , e160
Open AccessArtificial intelligence (AI) psychosis: mechanisms, clinical risks and safety considerations in generative AI chatbots
Summary: As generative artificial intelligence chatbots become embedded in everyday life, concerns about their psychological risks are growing. Emerging reports describe cases of artificial intelligence-induced or -associated psychosis (hereafter artificial intelligence (AI) psychosis) in which intensive chatbot use is associated with delusional thinking patterns. This paper proposes a provisional mechanism wherein baseline user vulnerabilities and engagement patterns interact with generative artificial intelligence characteristics, such as sycophancy and hallucination, contributing to delusional ideation. It subsequently outlines clinical, design and regulatory strategies that may help mitigate risks.
- Top Cited PapersOpen Access
- 20 May 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (10) , 1395
Safety Mechanisms and Risk Mitigation in Generative AI Mental Health Chatbots: A Systematic Scoping Review
Background: Generative AI (GenAI) mental health chatbots are increasingly being developed to help address persistent barriers to mental healthcare. Unlike earlier rule-based and retrieval-based systems, GenAI chatbots generate open-ended outputs that can be inaccurate and unsafe. Documented harms from general-purpose GenAI chatbots have highlighted the need for purpose-built interventions with dedicated safeguards, yet how safety is implemented in such interventions remains poorly understood. Methods: This scoping review followed the Joanna Briggs Institute methodology and PRISMA-ScR guidelines, with a prospectively registered and peer-reviewed protocol. A systematic search of seven academic databases and search engines including MEDLINE, Scopus, PsycINFO, ACM Digital Library, IEEE Xplore, Google Scholar and Consensus was conducted in July 2025. Two reviewers independently screened records and extracted data. Safety mechanisms and risk mitigation strategies were narratively synthesised across three pre-specified domains: technical safeguards, pre-deployment safety considerations, and delivery-phase risk mitigation strategies. Results: Twenty-one studies across 11 countries were included. Most interventions incorporated at least one technical safety mechanism, most commonly fine-tuning and prompt engineering. A smaller subset implemented layered safety architectures combining retrieval systems, content filters or risk classifiers, and rule-based algorithms. Pre-deployment safeguards included clinical expert and user co-design approaches, research ethics procedures, and data privacy measures. During intervention delivery, detailed onboarding with role clarification was common, but human oversight was limited. Crisis referral protocols varied in rigour but were mostly underdeveloped, and systematic adverse event monitoring was sparse. Documented safety failures included missed suicidal ideation and provision of inaccurate clinical information. Conclusions: GenAI chatbot interventions require a robust sociotechnical approach that integrates technical safeguards with user co-design, procedural controls, and human oversight. Future research is needed to evaluate efficacy, improve safeguards and standardise safety outcome measurement. Regulatory oversight proportional to the risks these systems carry is required to enable integration into stepped or blended mental healthcare.
- 20 May 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (10) , 1395
Top Cited PapersOpen AccessSafety Mechanisms and Risk Mitigation in Generative AI Mental Health Chatbots: A Systematic Scoping Review
Background: Generative AI (GenAI) mental health chatbots are increasingly being developed to help address persistent barriers to mental healthcare. Unlike earlier rule-based and retrieval-based systems, GenAI chatbots generate open-ended outputs that can be inaccurate and unsafe. Documented harms from general-purpose GenAI chatbots have highlighted the need for purpose-built interventions with dedicated safeguards, yet how safety is implemented in such interventions remains poorly understood. Methods: This scoping review followed the Joanna Briggs Institute methodology and PRISMA-ScR guidelines, with a prospectively registered and peer-reviewed protocol. A systematic search of seven academic databases and search engines including MEDLINE, Scopus, PsycINFO, ACM Digital Library, IEEE Xplore, Google Scholar and Consensus was conducted in July 2025. Two reviewers independently screened records and extracted data. Safety mechanisms and risk mitigation strategies were narratively synthesised across three pre-specified domains: technical safeguards, pre-deployment safety considerations, and delivery-phase risk mitigation strategies. Results: Twenty-one studies across 11 countries were included. Most interventions incorporated at least one technical safety mechanism, most commonly fine-tuning and prompt engineering. A smaller subset implemented layered safety architectures combining retrieval systems, content filters or risk classifiers, and rule-based algorithms. Pre-deployment safeguards included clinical expert and user co-design approaches, research ethics procedures, and data privacy measures. During intervention delivery, detailed onboarding with role clarification was common, but human oversight was limited. Crisis referral protocols varied in rigour but were mostly underdeveloped, and systematic adverse event monitoring was sparse. Documented safety failures included missed suicidal ideation and provision of inaccurate clinical information. Conclusions: GenAI chatbot interventions require a robust sociotechnical approach that integrates technical safeguards with user co-design, procedural controls, and human oversight. Future research is needed to evaluate efficacy, improve safeguards and standardise safety outcome measurement. Regulatory oversight proportional to the risks these systems carry is required to enable integration into stepped or blended mental healthcare.
- Open Access
- 31 December 2025
- Published by Wiley in Human Psychopharmacology: Clinical and Experimental
- Vol. 41 (1) , e70031
Anxiolytic Medication Use in Low‐ Middle‐ and High‐Income Countries: A World Mental Health Surveys Report
Background: Anxiolytic medications, particularly benzodiazepines, are widely prescribed, giving impetus to long‐standing debates about how often these agents should be employed in clinical practice. There are, however, few cross‐country studies of the pharmacoepidemiology of these agents. We report on the frequency of anxiolytic medication use, reasons for use, and perceived effectiveness of use in general population surveys across 20 countries. Methods: Face‐to‐face interviews with community samples totaling n = 49,919 respondents in the World Health Organization World Mental Health (WMH) Surveys asked about anxiolytic medication use anytime in the prior 12 months in conjunction with validated fully structured diagnostic interviews. Treatment questions were administered independently of diagnoses to all respondents. Results: A weighted 5.6% ( n = 4079) of respondents reported anxiolytic medication use within the past 12 months; the vast majority comprised benzodiazepine use, and use was highest amongst respondents with a subthreshold major depressive episode (MDE) (25.2%) and a 12‐month MDE (19.8%). Rates were significantly higher in high‐income countries (HICs) than low‐ and middle‐income countries (LMICs) (8.5% vs. 2.2%, χ 2 1 = 559.6, p < 0.001). Short‐acting benzodiazepines and z‐drugs were most commonly used for sleep (66.5% and 85.5%), while intermediate‐acting benzodiazepines and long‐acting benzodiazepines were most commonly used either for sleep (37.9% and 30.1%) or anxiety (33.3% and 32.0%). Across all conditions, anxiolytic medications were reported as very effective by 55.7% of users and somewhat effective by an additional 32.2% of users, with similar proportions in HICs and LMICs. Negative predictors of high perceived effectiveness were a 12‐month MDE and taking anxiolytic medication for comorbid anxiety and depression. Conclusion: These data do not definitely answer the question of how often benzodiazepines should be prescribed in clinical practice, but they usefully inform discussions of how to optimize their use. It is noteworthy that anxiolytic medications, particularly benzodiazepines, are largely prescribed for anxiety and sleep, and that they are widely perceived to be either very or somewhat effective by users. However, more targeted prescription of these agents may be necessary; in particular antidepressant intervention should be prioritized in the pharmacotherapy of major depressive disorder.
- 31 December 2025
- Published by Wiley in Human Psychopharmacology: Clinical and Experimental
- Vol. 41 (1) , e70031
Open AccessAnxiolytic Medication Use in Low‐ Middle‐ and High‐Income Countries: A World Mental Health Surveys Report
Background: Anxiolytic medications, particularly benzodiazepines, are widely prescribed, giving impetus to long‐standing debates about how often these agents should be employed in clinical practice. There are, however, few cross‐country studies of the pharmacoepidemiology of these agents. We report on the frequency of anxiolytic medication use, reasons for use, and perceived effectiveness of use in general population surveys across 20 countries. Methods: Face‐to‐face interviews with community samples totaling n = 49,919 respondents in the World Health Organization World Mental Health (WMH) Surveys asked about anxiolytic medication use anytime in the prior 12 months in conjunction with validated fully structured diagnostic interviews. Treatment questions were administered independently of diagnoses to all respondents. Results: A weighted 5.6% ( n = 4079) of respondents reported anxiolytic medication use within the past 12 months; the vast majority comprised benzodiazepine use, and use was highest amongst respondents with a subthreshold major depressive episode (MDE) (25.2%) and a 12‐month MDE (19.8%). Rates were significantly higher in high‐income countries (HICs) than low‐ and middle‐income countries (LMICs) (8.5% vs. 2.2%, χ 2 1 = 559.6, p < 0.001). Short‐acting benzodiazepines and z‐drugs were most commonly used for sleep (66.5% and 85.5%), while intermediate‐acting benzodiazepines and long‐acting benzodiazepines were most commonly used either for sleep (37.9% and 30.1%) or anxiety (33.3% and 32.0%). Across all conditions, anxiolytic medications were reported as very effective by 55.7% of users and somewhat effective by an additional 32.2% of users, with similar proportions in HICs and LMICs. Negative predictors of high perceived effectiveness were a 12‐month MDE and taking anxiolytic medication for comorbid anxiety and depression. Conclusion: These data do not definitely answer the question of how often benzodiazepines should be prescribed in clinical practice, but they usefully inform discussions of how to optimize their use. It is noteworthy that anxiolytic medications, particularly benzodiazepines, are largely prescribed for anxiety and sleep, and that they are widely perceived to be either very or somewhat effective by users. However, more targeted prescription of these agents may be necessary; in particular antidepressant intervention should be prioritized in the pharmacotherapy of major depressive disorder.
- Open Access
- 9 October 2025
- Published by Springer Nature in International Journal of Mental Health Systems
- Vol. 19 (1) , 1-11
Examining the effects of engagement with an app-based mental health intervention: a secondary analysis of a randomized control trial with treatment non-compliance
Minder is a mental health and substance use mobile application found to have a small but significant effects in a recent randomized trial. Poor engagement has been identified as a common threat to the effectiveness of digital mental health tools that is not accounted for in intention-to-treat analyses. The objective of this study is to conduct a prespecified secondary analyses to identify factors associated with engagement and examine the impact of engagement on trial outcomes. 1489 students were randomized to either the intervention (n = 743) or waitlist control (n = 746). Primary outcomes were changes in anxiety (General Anxiety Disorder 7 (GAD-7)), depression (Patient Health Questionnaire 9 (PHQ-9)), and alcohol consumption (US Alcohol Use Disorders Identification Test-Consumption Scale (USAUDIT-CS)) at 30-days. Secondary outcomes included frequency of substance use and mental wellbeing (Short Warwick-Edinburgh Mental Wellbeing Scale (SWEMWS)). A Complier Average Causal Effect (CACE) analysis was conducted using 3 separate criteria reflecting differing engagement levels: (1) a binary measure: use of any app component, (2) a continuous measure: number of unique days of app use, and (3) an ordinal measure: number of components accessed within the app. 80.4% of participants used at least one app feature. Statistically significant differences were observed in app utilization across gender, ethnicity, having a history of depression or anxiety, higher baseline PHQ-9, higher SWEMWS, and poor/fair overall self-assessed mental and physical health. Any use of Minder was associated with significantly lower scores on the GAD-7 (adjusted group mean difference = − 1.09, 95% CI − 1.60 to − 0.57; P < .01) and PHQ-9 (adjusted group mean difference = − 0.84, 95% CI − 1.41 to − 0.27; P < .01) with increasing number of unique utilization days or components accessed associated with increased reductions. Any use of Minder was associated with significantly higher scores on the SWEMWS (adjusted group mean difference = 0.93, 95% CI 0.46 to 1.39; P < .01) and lower frequency of cannabis use (adjusted group mean difference = − 0.15, 95% CI − 0.23 to − 0.06; P < .01) with increased app utilization associated with larger improvements. The CACE analysis identified significant dose-response relationships indicating that increased use of the Minder app leads to larger effects that can reach levels of clinical significance. ClinicalTrials.gov NCT05606601 (November 3, 2022); https://clinicaltrials.gov/ct2/show/NCT05606601 .
- 9 October 2025
- Published by Springer Nature in International Journal of Mental Health Systems
- Vol. 19 (1) , 1-11
Open AccessExamining the effects of engagement with an app-based mental health intervention: a secondary analysis of a randomized control trial with treatment non-compliance
Minder is a mental health and substance use mobile application found to have a small but significant effects in a recent randomized trial. Poor engagement has been identified as a common threat to the effectiveness of digital mental health tools that is not accounted for in intention-to-treat analyses. The objective of this study is to conduct a prespecified secondary analyses to identify factors associated with engagement and examine the impact of engagement on trial outcomes. 1489 students were randomized to either the intervention (n = 743) or waitlist control (n = 746). Primary outcomes were changes in anxiety (General Anxiety Disorder 7 (GAD-7)), depression (Patient Health Questionnaire 9 (PHQ-9)), and alcohol consumption (US Alcohol Use Disorders Identification Test-Consumption Scale (USAUDIT-CS)) at 30-days. Secondary outcomes included frequency of substance use and mental wellbeing (Short Warwick-Edinburgh Mental Wellbeing Scale (SWEMWS)). A Complier Average Causal Effect (CACE) analysis was conducted using 3 separate criteria reflecting differing engagement levels: (1) a binary measure: use of any app component, (2) a continuous measure: number of unique days of app use, and (3) an ordinal measure: number of components accessed within the app. 80.4% of participants used at least one app feature. Statistically significant differences were observed in app utilization across gender, ethnicity, having a history of depression or anxiety, higher baseline PHQ-9, higher SWEMWS, and poor/fair overall self-assessed mental and physical health. Any use of Minder was associated with significantly lower scores on the GAD-7 (adjusted group mean difference = − 1.09, 95% CI − 1.60 to − 0.57; P < .01) and PHQ-9 (adjusted group mean difference = − 0.84, 95% CI − 1.41 to − 0.27; P < .01) with increasing number of unique utilization days or components accessed associated with increased reductions. Any use of Minder was associated with significantly higher scores on the SWEMWS (adjusted group mean difference = 0.93, 95% CI 0.46 to 1.39; P < .01) and lower frequency of cannabis use (adjusted group mean difference = − 0.15, 95% CI − 0.23 to − 0.06; P < .01) with increased app utilization associated with larger improvements. The CACE analysis identified significant dose-response relationships indicating that increased use of the Minder app leads to larger effects that can reach levels of clinical significance. ClinicalTrials.gov NCT05606601 (November 3, 2022); https://clinicaltrials.gov/ct2/show/NCT05606601 .
- Open Access
- 22 February 2025
- Published by Springer Nature in BMC Public Health
- Vol. 25 (1) , 1-10
Excess mortality in COVID-19-negative people with non-communicable disorders during the first pandemic wave
Background: Estimating the indirect mortality due to COVID-19 is of the utmost importance to develop adequate public health policy during future outbreaks. Methods: From province-wide administrative datasets, we identified British Columbians who tested negative for COVID-19 during the first wave and never tested positive throughout 2020. We obtained a pre-pandemic (2018) cohort matched on age, sex, history of non-communicable disorders (NCDs), multimorbidity, and severity/acuity, and implemented a doubly robust estimation of the effect of the first pandemic wave on mortality. Results: The adjusted odds ratio (AOR) of death was 3.2 times higher for a 2020 cohort who tested negative for COVID-19 (n = 123,133), compared to matched pre-pandemic controls. In both cohorts, a majority (72.5%) experienced at least one pre-existing NCD. Stratification by NCD shows an AOR of death ranges between 2–for people with substance use disorders– and 7–for people previously undiagnosed with NCDs (e.g., incident cases that went untreated). The largest subgroup was composed of people with mental disorders (47,413 people), with an AOR of death of 2.5. Though the COVID-19 direct mortality in the general population remained low (1.9 per 10,000), the excess mortality in this COVID-negative cohort was extremely high − 4,085 of the 123,133– which entails a minimum indirect excess mortality death rate of 6.5 per 10,000 in the general population. Conclusions: During the first pandemic year, mortality in COVID-negative adults was several times greater than before COVID-19, in people with matched NCD distribution and severity. Our findings suggest that low direct COVID-19 mortality was accompanied by less visible–but much higher– indirect mortality due to undiagnosed and/or untreated NCDs, highlighting the need to focus not only on mitigating the harms of new agents, but also of continuing service delivery for treatable conditions.
- 22 February 2025
- Published by Springer Nature in BMC Public Health
- Vol. 25 (1) , 1-10
Open AccessExcess mortality in COVID-19-negative people with non-communicable disorders during the first pandemic wave
Background: Estimating the indirect mortality due to COVID-19 is of the utmost importance to develop adequate public health policy during future outbreaks. Methods: From province-wide administrative datasets, we identified British Columbians who tested negative for COVID-19 during the first wave and never tested positive throughout 2020. We obtained a pre-pandemic (2018) cohort matched on age, sex, history of non-communicable disorders (NCDs), multimorbidity, and severity/acuity, and implemented a doubly robust estimation of the effect of the first pandemic wave on mortality. Results: The adjusted odds ratio (AOR) of death was 3.2 times higher for a 2020 cohort who tested negative for COVID-19 (n = 123,133), compared to matched pre-pandemic controls. In both cohorts, a majority (72.5%) experienced at least one pre-existing NCD. Stratification by NCD shows an AOR of death ranges between 2–for people with substance use disorders– and 7–for people previously undiagnosed with NCDs (e.g., incident cases that went untreated). The largest subgroup was composed of people with mental disorders (47,413 people), with an AOR of death of 2.5. Though the COVID-19 direct mortality in the general population remained low (1.9 per 10,000), the excess mortality in this COVID-negative cohort was extremely high − 4,085 of the 123,133– which entails a minimum indirect excess mortality death rate of 6.5 per 10,000 in the general population. Conclusions: During the first pandemic year, mortality in COVID-negative adults was several times greater than before COVID-19, in people with matched NCD distribution and severity. Our findings suggest that low direct COVID-19 mortality was accompanied by less visible–but much higher– indirect mortality due to undiagnosed and/or untreated NCDs, highlighting the need to focus not only on mitigating the harms of new agents, but also of continuing service delivery for treatable conditions.
- Top Cited Papers
- 18 February 2025
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 183, 225-236
Prevalence, age-of-onset, and course of mental disorders among 72,288 first-year university students from 18 countries in the World Mental Health International College Student (WMH-ICS) initiative
- 18 February 2025
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 183, 225-236
Top Cited PapersPrevalence, age-of-onset, and course of mental disorders among 72,288 first-year university students from 18 countries in the World Mental Health International College Student (WMH-ICS) initiative